Drug Type CAR-NK |
Synonyms IL-15-armored anti-claudin 18.2 CAR NK-cell therapySimnova Biotechnology) |
Target |
Action inhibitors |
Mechanism CLDN18.2 inhibitors(Claudin 18.2 inhibitors) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
License Organization- |
Drug Highest PhasePreclinical |
First Approval Date- |
Regulation- |
| Indication | Highest Phase | Country/Location | Organization | Date |
|---|---|---|---|---|
| Advanced gastric carcinoma | Preclinical | China | 05 Nov 2024 |





